Carboquone therapy for hematologic neoplasms.

Abstract

A daily oral dose of 1-2 mg of Carboquone was administered for remission induction to 38 patients with hematologic malignancy, and the following results were obtained: 2 of the 3 patients with malignant lymphoma, 1 of the 12 patients with multiple myeloma, 13 of the 14 patients with chronic myelogenous leukemia, and all 9 patients with polycythemia vera attained complete remission.

• Authors: Y Uzuka, Y Saito, H Takahashi, M Komatsu
• Journal: The Tohoku journal of experimental medicine (Tohoku J Exp Med) Vol. 138 Issue 2 Pg. 151-60 (Oct 1982) ISSN: 0040-8727 [Print] Japan
• PMID: 6960553 (Publication Type: Journal Article)

Chemical References

• Azirines
• Carbazilquinone

Topics

• Administration, Oral
• Adult
• Aged
• Azirines (therapeutic use)
• Carbazilquinone (administration & dosage, therapeutic use)
• Female
• Humans
• Leukemia, Myeloid (drug therapy)
• Lymphoma (drug therapy)
• Male
• Middle Aged
• Multiple Myeloma (drug therapy)
• Polycythemia Vera (drug therapy)